Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (324)	12/4/2001 11:19:35 AM
From: thebeach	Read Replies (1) \| Respond to of 356

Procyon Enters into Cancer Technology Option Agreement with Stanford University - Potential applications in therapy for prostate, breast and thyroid cancers MONTREAL, Dec. 4 /CNW/ - Procyon Biopharma Inc announced today the signing of an exclusive technology option agreement with Stanford University, California, for the potential anticancer applications of the technology developed by Drs. Aaron Hsueh and Brian Kobilka. The option grants Procyon an exclusivity period of upto 18 months to assess the technology protected by a US Patent and described as "Soluble 7-Transmembrane Domain G_Protein Coupled Receptor Compositions and Methods". Prospective Licensing Terms are also part of the agreement. In their invention, Drs. Hsueh and Kobilka describe the isolation and characterization of soluble glycoprotein hormone receptors for LH (Lutenizing hormone), FSH (Follicle stimulating hormone) and TSH (Thyroid stimulating hormone). Elevated levels of these hormones are implicated in steroid dependent cancers such as breast cancer, prostate cancer and thyroid cancer. High FSH levels are also believed to be responsible for "hot flushes" experienced by prostate cancer patients undergoing hormonal therapy. A potential application of the cloned receptors could be in the treatment of such cancers. As an example, the administration of an extracellular soluble FSH receptor to a breast cancer patient, leading to a binding of the patient's FSH molecules, could potentially lead to preventing or reducing the ability of the FSH to induce the ovarian cells to produce estrogens, high levels of which, particularly in post-menopausal women, have been implicated with predisposition to breast cancer. Similarly, an administration of extra cellular ligand binding domain of the LH receptor could be used to lower the levels of testosterone which at high levels promotes growth of prostate cancer. "We are very intrigued by the invention of Drs.Hsueh and Kobilka and intend to fully evaluate the potential applications of the soluble receptors for cancer therapy," stated Hans Mader, President and CEO of Procyon. "We believe the Stanford technology is very promising and complements our R & D as well as planned clinical studies with our lead drug candidate PCK3145 for the treatment of hormone resistant prostate cancer", Mr. Mader further stated. Procyon BioPharma Inc. is a publicly listed, biopharmaceutical Company focused principally on advancing two powerful platform technologies that have the potential to diagnose and treat cancer. Procyon's non-pathogenic Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP94) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. In addition, the estimation of PSP94 levels in prostate cancer patients may have prognostic and diagnostic applications. Procyon also has two late-stage products: FIBROSTAT(R), a topical cream for the management of newly formed scars following surgery or burns and COLOPATH(R), a rapid, non-invasive screening test for colorectal cancer. Procyon's shares trade on the Toronto Stock Exchange under the ticker symbol, PBP.